V ClinBio Acquires 49.98% Stake in Cellix to Advance Synergix, a Transformative Pro-drug Technology Platform
06 févr. 2018 11h15 HE | V ClinBio Inc.
- Lead compounds for the treatment of relapsing-remitting multiple sclerosis and ulcerative colitis on target to enter clinic in 2018 - PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- V ClinBio...